You are here

Database of TGA listed medicine compliance review results

30 June 2020

Important information about this database

Safety alerts

When serious safety or quality issues are identified with therapeutic goods, this information and any recommendations are posted immediately on the Safety information pages of the TGA website.

Listed medicines are included on the Australian Register of Therapeutic Goods (ARTG) without undergoing pre-market evaluation by TGA. This relies on them satisfying certain criteria to ensure they are low risk and the sponsor certifying that their medicine meets all of the requirements of the Therapeutic Goods Act 1989.

To monitor the safety, quality and efficacy of listed medicines and ensure they meet all requirements once they are on the market, each year the TGA conducts listed medicine compliance reviews on a proportion of those on the ARTG.

If during a compliance review, a medicine is found to not comply with regulatory requirements, the TGA will notify the sponsor and take action according to the risk posed by the medicine to the consumer. The sponsor may be required to resolve the identified issues (such as update their listing or medicine labels) to bring the listed medicine into compliance. In some cases, the medicine may not to be cancelled from the ARTG, meaning that it can no longer be lawfully supplied to the consumer. Sponsors may also respond with further information to refute conclusions derived during the compliance of their medicine.

This database makes information publically available about the results of TGA's compliance reviews of individual listed medicines. The information contained within the database will assist consumers to make an informed choice about whether a specific listed medicine is safe and does what it says it does, as well as what actions the consumer is recommended to take in response to the findings of the review.

Descriptions of identified issues are provided if they relate to the safety and efficacy of a medicine. Details about minor issues, such as those of an administrative nature, are not provided.

Publication of results only occurs once the compliance review has been concluded, after sponsor has had the opportunity to consider our findings and actions have been undertaken to address any identified issues.

Results are released quarterly.

More information about the publication of compliance review results and this database is provided for sponsors on the post-market compliance reviews web page.

Brief descriptions of the information presented in this database are included below.

ARTG ID: The unique identification code of a product included in the Australian Register of Therapeutic Goods (ARTG). The ARTG ID for listed medicines starts with an 'AUST' and is followed by an 'L' and a sequence of numbers. The ARTG number is displayed on a medicine/s main label.

Review outcome: Indicates whether the medicine is still permitted to be supplied following the compliance review due to whether it remains on the ARTG or not. This may include information on any corrective action taken by sponsors to address identified issues so that the medicine can continue to be included on the ARTG and supplied.

If the review outcome states that a medicine is 'no longer permitted to be supplied' this does not necessarily mean that there were issues with a particular medicine or that it is unsafe to continue using. A sponsor may voluntarily choose to stop supplying and marketing their medicine to consumers and cancel it from the ARTG. If this occurs, the outcome of the review will reflect that the medicine is no longer permitted for supply.

Is it safe to continue using this medicine?: This is indicated by a 'yes' or 'no', with specific directions provided as required.

The database indicates whether the medicine is safe based only on the assessment performed and information reviewed by the TGA at a point in time. The TGA may not assess the safety of an individual product during a compliance review. This may occur for various reasons including when the safety of the product was not a focus of the review or the sponsor chooses to cease the supply or marketing of a particular product during a compliance review. As Listed medicines must meet certain low risk criteria and sponsors must certify that their medicine is safe for use before they supply it, it is assumed to be safe to continue using the medicine based on the sponsor's certification despite the safety of the medicine having not been reviewed by the TGA.

What action should consumers take?: A summary of any recommended actions for consumers if they have taken or intend to take the medicine.

Sponsor: The sponsor of a product refers to the sponsor at the time the product was reviewed by the TGA. The current sponsor for the product may have changed in the time since the product was reviewed. The current sponsor of a listed medicine product is displayed in the ARTG.

How was this medicine selected for review?: A listed medicine may be selected randomly or be targeted for a review. Further information is provided at: Listed medicines compliance reviews.

Information reviewed: The information the TGA evaluated during the compliance review to determine whether the medicine met the relevant legal requirements. The type of information reviewed can include: the ARTG record of the medicine; labels; advertising; manufacturing documentation; scientific or traditional evidence supporting what the medicine claims to do; laboratory testing results. A compliance review can evaluate some or all of this information.

Issues related to safety: A summary of any issues identified during the compliance review that:

  • have the potential or are likely to affect consumer safety
  • are breaches of legal requirements that are in place to ensure the low-risk status of listed medicines, even if they are unlikely to pose a significant risk to consumer health and safety

Issues related to efficacy: A summary of any issues identified during the compliance review that may, or do, affect product efficacy (that the medicine does what it says it will do).

Actions taken during the review: A summary of the actions that the TGA and the sponsor took during the compliance review to address any issues identified by the TGA, for example: TGA requiring the sponsor to correct the identified issues with their medicine.

Cancellation effective date (if applicable): If a listed medicine is cancelled from the ARTG by the TGA following a compliance review, the date the medicine was no longer listed on the ARTG. Where a medicine is cancelled from the ARTG, it cannot be supplied or marketed by the sponsor.

Date of review outcome/conclusion: The date the compliance review was closed by the TGA, which is after we consider a sponsor's submissions and any actions they took to rectify any identified issues.

Publication date: The date the compliance review information was published in the database.

Decision status (if applicable): If a listed medicine is cancelled from the ARTG by the TGA following a compliance review but this decision is later appealed and the decision to cancel is overturned.

Additional information (if applicable): Any other relevant information about the medicine.

For further information, please contact Complementary Medicines and OTC Medicines Branch via phone on 1800 020 653 or via email at complementary.medicines@health.gov.au.

Disclaimer about the release of information in this database

While reasonable care is taken to ensure that the information included in the database is an accurate record of the results and outcomes of TGA's listed medicines compliance reviews, the TGA does not guarantee or warrant the accuracy, reliability, completeness or currency of the information or its usefulness in achieving any purpose.

To the fullest extent permitted by law, including but not limited to section 61A of the Therapeutic Goods Act 1989, the TGA will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on this information.

Displaying 1 - 10 of 35

Compliance review results

antiVIRII

Date of review outcome: 30 Mar 2020

Publication date: Jun-2020

ARTG ID: 330995

Review outcome:

Medicine is no longer permitted to be supplied

Is it safe to continue using this medicine?

Yes, based on the sponsor's certification

What action should consumers take?

None

Sponsor

BlueSkyGreenEarth Herbs Pty Ltd

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Website

Issues related to safety

The safety of the medicine was not assessed as part of this review

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

The sponsor cancelled the medicine and withdrew it from further supply. The sponsor updated their website to remove references to supply of the medicine in Australia.

Bioglan Ashwagandha

Date of review outcome: 6 Mar 2020

Publication date: Jun-2020

ARTG ID: 289121

Review outcome:

Medicine is no longer permitted to be supplied

Is it safe to continue using this medicine?

Yes

What action should consumers take?

Consider whether the medicine is right for you given that the claims about the medicine were not substantiated. These claims related to the traditional use of the medicine in the Ayurvedic tradition as a rejuvenative tonic, an anti-inflammatory, an aphrodisiac and sleep aid, to calm the mind, relieve nervous tension, irritability and mild anxiety, support the nervous system, support cognitive function, memory and mental concentration, support immune and adrenal gland health, assist with recovery from illness, pacify and relieve Kapha and Vata, help the body adapt to stress and support longevity.

Sponsor

Natural Bio Pty Limited

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Evidence, Labels, Manufacturing Documentation, Website

Issues related to safety

None

Issues related to efficacy

The sponsor did not hold sufficient evidence to support the advertised claims in relation to the traditional Ayurvedic use of the medicine, detailed in 'What action should consumers take?' above. The evidence was not sufficient because the traditional methods of preparing the ingredients did not align with that used in the medicine. In some cases, scientific evidence was used inappropriately to support advertised claims based on a tradition of use in Ayurvedic medicine.

Actions taken during the review

TGA required the sponsor to correct the issues with the medicine. The sponsor cancelled the medicine and withdrew it from further supply.

BLACKMORES PROBIOTICS+ ECZEMA RELIEF

Date of review outcome: 11 Mar 2020

Publication date: Jun-2020

ARTG ID: 281660

Review outcome:

Medicine continues to be permitted for supply. Batches released from 30 May 2020 must carry a corrected label.

Is it safe to continue using this medicine?

Yes

What action should consumers take?

If dissolving capsule contents in water or milk, consume immediately

Sponsor

Blackmores Ltd

How was this medicine selected for review?

Random

Information reviewed

ARTG Record, Labels, Website

Issues related to safety

None

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct the minor issues with the medicine. The sponsor updated the label of the medicine to correct these issues.

BLUE WATER WEALTHY HEALTH SQUALENE 1000mg

Date of review outcome: 9 Apr 2020

Publication date: Jun-2020

ARTG ID: 128967

Review outcome:

Medicine continues to be permitted for supply. Batches released from 9 April 2020 must carry a corrected label.

Is it safe to continue using this medicine?

Yes

What action should consumers take?

None

Sponsor

Universal Pharmaceuticals Pty Ltd

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Labels, Laboratory Results, Manufacturing Documentation, Sample, Website

Issues related to safety

None

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct a minor issue with the medicine. The sponsor updated the label and website of the medicine to correct this issue.

Cancer_Council Ultra Sunscreen Lotion SPF50+

Date of review outcome: 18 Mar 2020

Publication date: Jun-2020

ARTG ID: 287253

Review outcome:

Medicine continues to be permitted for supply

Is it safe to continue using this medicine?

Yes

What action should consumers take?

None

Sponsor

VitalityBrands Worldwide Pty Ltd

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Labels, Website

Issues related to safety

None

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct minor issues with the medicine. The sponsor updated the ARTG listing and website of the medicine to correct these issues.

Cancer_Council Ultra Sunscreen SPF50+

Date of review outcome: 18 Mar 2020

Publication date: Jun-2020

ARTG ID: 274938

Review outcome:

Medicine continues to be permitted for supply. Batches released from 25 February 2020 must carry a corrected label.

Is it safe to continue using this medicine?

Yes

What action should consumers take?

None

Sponsor

VitalityBrands Worldwide Pty Ltd

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Labels, Website

Issues related to safety

None

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct minor issues with the medicine. The sponsor updated the label and the website of the medicine to correct these issues.

Coles Echinacea, Garlic, Vitamin C & Zinc

Date of review outcome: 6 Apr 2020

Publication date: Jun-2020

ARTG ID: 300724

Review outcome:

Medicine continues to be permitted for supply. Batches released from 1 June 2020 must carry a corrected label.

Is it safe to continue using this medicine?

Yes, if you follow the recommended actions below

What action should consumers take?

Consider whether this medicine is right for you, taking note of its active ingredients. These may be found in the ARTG summary for the medicine on the TGA website.

Sponsor

IVC Brunel Healthcare Pty Ltd

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Labels, Website

Issues related to safety

None

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct the minor issues with the medicine. The sponsor updated the label of the medicine to correct these issues.

DRYeye Forte

Date of review outcome: 29 May 2020

Publication date: Jun-2020

ARTG ID: 281943

Review outcome:

Medicine continues to be permitted for supply

Is it safe to continue using this medicine?

Yes, if you follow the recommended actions below

What action should consumers take?

Seek advice from a suitably qualified health professional if you have been using this medicine to relieve symptoms associated with serious eye conditions such as blepharitis, meibomian gland disorder and Sjögren's Syndrome

Sponsor

MD Eyecare Pty Ltd

How was this medicine selected for review?

Random

Information reviewed

ARTG Record, Labels, Website

Issues related to safety

The website of the medicine contained claims about serious forms of eye diseases including blepharitis, meibomian gland disorder and Sjögren's Syndrome. Listed medicines are not permitted to refer to serious conditions such as those above without TGA approval. Use of such claims, without involvement of a suitably qualified health professional, may lead to inappropriate use of this medicine by consumers and pose significant risks to the management of their condition.

Issues related to efficacy

The website of the medicine contained a claim that the medicine is ideal for dry eye syndrome associated with blepharitis, hormonal changes, air-conditioning, air travel, Sjögren's Syndrome, and environmental factors. However, the claim was not covered by the sponsor's certification that they held evidence to substantiate it.

Actions taken during the review

TGA required the sponsor to correct the issues with the medicine. The sponsor updated the website of the medicine to remove the claims that referred to serious forms of diseases/conditions. In addition, the sponsor updated the ARTG listing of the medicine to correct these issues.

EGO SUNSENSE ULTRA

Date of review outcome: 13 May 2020

Publication date: Jun-2020

ARTG ID: 194260

Review outcome:

Sunscreen is no longer permitted to be supplied

Is it safe to continue using this medicine?

Yes, if you follow the recommended actions below

What action should consumers take?

If you are using this sunscreen, ensure you apply it 20 minutes prior to sun exposure

Sponsor

Ego Pharmaceuticals Pty Ltd

How was this medicine selected for review?

Targeted

Information reviewed

ARTG Record, Labels, Manufacturing Documentation, Website

Issues related to safety

The directions for use instructed consumers to apply the product 15 minutes prior to sun exposure as opposed to 20 minutes prior to sun exposure. It is important to ensure adequate time between application and sun exposure to maximise ultraviolet protection. However, the five minute difference is unlikely to pose an immediate safety risk to consumers.

Issues related to efficacy

The efficacy of the sunscreen was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct the issues with the sunscreen. The sponsor cancelled the sunscreen and withdrew it from further supply.

GRIPP-HEEL

Date of review outcome: 7 May 2020

Publication date: Jun-2020

ARTG ID: 62225

Review outcome:

Medicine continues to be permitted for supply. Batches released from 30 June 2020 must carry a corrected label with the warning statement 'Adults only'.

Is it safe to continue using this medicine?

Yes, however use of the medicine may pose a safety risk for some people. Follow the recommended actions below.

What action should consumers take?

Do not administer this medicine to children under the age of 18 years. Seek advice from a suitably qualified health practitioner if you have been doing so.

Sponsor

Brauer Professional Pty Ltd

How was this medicine selected for review?

Targeted (see Additional Information below)

Information reviewed

ARTG Record, Labels, Laboratory Results, Manufacturing Documentation

Issues related to safety

The medicine contains a herbal ingredient (Aconitum napellus) in an amount which is only allowed for use in listed medicines in adults. However, the label of the medicine lacked a warning statement that the medicine should only be used in adults. These restrictions are in place to ensure the safe use of listed medicines. However, current data indicates that the amount of Aconitum napellus in the medicine is unlikely to pose an immediate safety risk to children.

Issues related to efficacy

The efficacy of the medicine was not assessed as part of this review

Actions taken during the review

TGA required the sponsor to correct the issues with the medicine. The sponsor updated the label of the medicine to include the warning statement 'Adults only'.
This medicine was targeted to check its compliance with quantity and labelling requirements related to the ingredient Aconitum spp.

Pages